Pacira BioSciences (PCRX) Enterprise Value (2010 - 2026)

Pacira BioSciences' Enterprise Value history runs 17 years deep, the most recent figure standing at -$202.2 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 59.04% year-over-year to -$202.2 million; the TTM figure through Mar 2026 stood at -$202.2 million (up 59.04% YoY), while the FY2025 annual figure was -$238.4 million, up 50.8% from the prior year.
• Enterprise Value was -$202.2 million for Q1 2026 at Pacira BioSciences, up from -$238.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$174.0 million in Q1 2023 to a low of -$493.6 million in Q1 2025.
• Historically, Enterprise Value has averaged -$328.8 million across 5 years, with a median of -$316.4 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value surged 61.52% in 2023, then tumbled 92.96% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$288.7 million in 2022, then gained by 3.49% to -$278.6 million in 2023, then slumped by 73.96% to -$484.6 million in 2024, then surged by 50.8% to -$238.4 million in 2025, then increased by 15.2% to -$202.2 million in 2026.
• The last three Enterprise Value figures came in at -$202.2 million (Q1 2026), -$238.4 million (Q4 2025), and -$246.3 million (Q3 2025), per Business Quant data.